TREATMENT OPTIMIZATION AT A LOW AND HIGH RISK OF RESISTANCE OF MALIGNANT TROPHOBLASTIC TUMORS IN WOMEN OF THE REPUBLIC OF TAJIKISTAN
Abstract
Aim. To optimize the treatment of patients with malignant trophoblastic tumors (MTT) in the Republic of Tajikistan.
Material and methods. The clinical material for this study was data on 118 patients with MTT treated in the Department of Oncogynecology and Chemotherapy of the State Institution “Republican Cancer Research Center” of the MoHSP RT from 2016 to 2019.
Results discussion. Treatment of all patients started with standard first-line chemotherapy, with a low risk of developing tumor resistance in the methotrexate/leucovorin (Mtx/FA) regimen, with a high risk of developing tumor resistance in the EMA-CO, MAC, and MAP regimen. Thus, the effectiveness of first-line chemotherapy in MTT patients was 94%.
Conclusion. It is extremely important to determine the degree of risk of MTT resistance to select the optimal chemotherapy regimen. The standard line I chemotherapy regimen (MTX/FA - for low risk of resistance and EMA-CO, MAC and MAP for high risk) are highly effective MTT treatment regimens and can be considered the optimal choice regimens.
About the Authors
D. R. Sanginov
SEI Avicenna Tajik State Medical University
Tajikistan
Tajikistan
Department of Oncology
M. A. Sattorova
SL «Repablic Oncology scientific center» of the MHSP RT ROSC
Tajikistan
Tajikistan
Sattorova Mokhiniso Abdultabobovna
Tajikistan, Dushanbe, st. A. Navoi, 45/1, apt. ten;
В. А. Numonova
SL «Repablic Oncology scientific center» of the MHSP RT ROSC
Tajikistan
Tajikistan
References
1. Al-shukri S. Kh. Benign urethral neoplasms in women.
2. Kozachenko V. P. Klinicheskaya onkoginekologiya. Rukovodstvo dlya vrachey [Clinical Oncogynecology. A Guide for Physicians]. Moscow, Binom Publ., 2016. 424 p.
3. Meshcheryakova L. A. Trofoblasticheskaya bolezn. Onkoginekologiya. Natsionalnoe rukovodstvo [Trophoblastic disease. Oncogynecology]. Moscow, GEOTAR-Media Publ., 2019. 273-293 p.
4. Nevozhay D. V. Sovremennye predstavleniya o mekhanizme protivoopukholevogo deystviya metotreksata i ustoychivosti k nemu [Current understanding of the mechanism of antitumor action and resistance to methotrexate]. Pacific journal of medical sciences, 2006, No. 4, pp. 12-16;
5. Tsip N. P. Khimioterapiya pri trofoblasticheskikh opukholyakh, razvivayushchikhsya posle evakuatsii puzyrnogo zanosa [Chemotherapy for trophoblastic tumors developing after evacuation of the bulla]. Onkologiya - Oncology, 2015, No. 3, pp. 252-254.
6. Chapman-Davis E., Hoekstra A. V., Rademaker A.W., Schink J.C., Lurain J.R. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single agent methotrexate chemotherapy. Gynecologic Oncology, 2012, No. 125 (3), pp. 572–575.
7. Goldstein D. P., Berkowitz R. S. Current management of gestational trophoblastic neoplasia. Hematology/Oncology Clinics of North America, 2012, No. 26 (1), pp. 111–131.
8. Lybol C., Sweep F.C.G.J., Harvey R., Mitchell H., Short D., Thomas C.M.G. et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecologic Oncology, 2012, No. 125 (3), pp. 576–579.
9. Salerno A. The incidence of gestational trophoblastic disease in Italy: a multicenter study. Journal of Reproductive Medicine, 2012, No. 57 (5–6), pp. 204–206.
10. Seckl M. J., Sebire N. J., Fisher R. A. et al. Gestational trophoblastic disease: ESMO clinical practice guidelines. Annals of Oncology, 2015, Vol. 24, Suppl. 6, pp. vi39-vi50.
Review
For citations:
Sanginov D.R., Sattorova M.A., Numonova В.А. TREATMENT OPTIMIZATION AT A LOW AND HIGH RISK OF RESISTANCE OF MALIGNANT TROPHOBLASTIC TUMORS IN WOMEN OF THE REPUBLIC OF TAJIKISTAN. Health care of Tajikistan. 2021;(1):62-67. (In Russ.)
Views:
398
Email this article 